Thursday, February 9, 2012 Last update: 3:33 PM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Decision Resources
News articles for Decision Resources:
Thursday, February 9, 2012
- In 2020, Regeneron/Bayer Healthcare’s Eylea Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Diabetic Macular EdemaDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought ... read more
Thursday, February 2, 2012
- Pertuzumab Plus Trastuzumab and Docetaxel Will Become Decision Resources’ Proprietary Clinical Gold-Standard Treatment for Metastatic First-Line HER2-Positive Breast Cancer in 2015Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought ... read more
Wednesday, February 1, 2012
- Surveyed U.S. Endocrinologists Indicate They Would Prescribe Amylin/Alkermes’ Bydureon to 20 Percent of Their Patients with Type 2 DiabetesDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. endocrinologists indicate that they would prescribe Amylin/Alkermes’ ... read moreSurveyed U.S. Cardiologists Indicate That They Would Prescribe Cardiome/Merck’s Oral Vernakalant and Gilead/Menarini’s Ranolazine to 13 Percent of Their Atrial Fibrillation PatientsDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. cardiologists indicate that they would prescribe Cardiome/Merck’s oral ... read more
Monday, January 23, 2012
- Decision Resources Group to Bring Its One-Day Oncology Seminar to San FranciscoDecision Resources Group is bringing its Competitive Landscape Seminar Series: Oncology to the West Coast. This one-day seminar, developed specifically for pharmaceutical and biotech ... read more
Thursday, December 22, 2011
- CORRECTING and REPLACING Linaclotide Will Become the New Market Leader and Achieve Blockbuster Status by 2018 for the Treatment of Irritable Bowel SyndromeSecond graph, first sentence of release dated December 21, 2011 should read: ...from $610 million in 2010 to $2.7 billion in 2020... (sted ...from $610 million in 2010 ... read more
Wednesday, December 21, 2011
- Linaclotide Will Become the New Market Leader and Achieve Blockbuster Status by 2018 for the Treatment of Irritable Bowel SyndromeDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its superb efficacy, safety profile and anticipated launch ... read more
Monday, December 19, 2011
- For the Treatment of Type 2 Diabetes, the Vast Majority of Surveyed Physicians in China and South Korea Indicate That There is a Need for GLP-1 Analogues Other Than ByettaDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that in both China and South Korea, the vast majority of ... read more
Wednesday, December 14, 2011
- Russia’s Non-Small-Cell Lung Cancer Drug Market Will Grow to $163 Million in 2015Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the Russian market for non-small-cell lung cancer therapies will grow ... read more
Tuesday, December 13, 2011
- Moderate Growth in the Crohn’s Disease Drug Market Will Mask Dramatic Changes as Sales of Newer and Emerging Agents Will Outpace the Decline in Sales of Older, Established AgentsDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2010 to 2020, the Crohn’s disease drug market will ... read moreThe Current Market Leader in Epilepsy, Levetiracetam, Will Maintain Its Market-Leading Status Through 2020Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the current leading agent in the epilepsy drug market, levetiracetam ... read more
Monday, December 12, 2011
- Through 2020, Generic Erosion of Blockbuster Agents Will Be a Major Contributor to a Nearly $6 Billion Decrease in the Dyslipidemia Drug MarketDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2020, the generic erosion of blockbuster agents—most notably Pfizer’s ... read moreThe Combined Markets for Drugs Used in the Treatment and Prophylaxis of Venous Thromboembolism Will Increase from $3.4 Billion in 2010 to $4.7 Billion in 2020Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launches and strong uptake of oral ... read moreFollowing a Near-Term Market Decline, the Launch of New Acute Therapies and Increasing Uptake of Allergan’s Botox Will Drive the Migraine Drug Market to Increase to $4.4 Billion in 2020Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of key agents—including the continued generic erosion of ... read more
Thursday, December 8, 2011
- Through 2020, the Asthma Drug Market Will Remain Flat Amidst Generic Erosion of Key Agents and Increased Product CompetitionDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the uptake of high-price once-daily combinations and novel anticytokine ... read moreThrough 2020, Genentech/Roche/Chugai’s Avastin Will Be Minimally Challenged as the Market Leading Therapy for Colorectal CancerDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that Genentech/Roche/Chugai’s Avastin will be minimally challenged over the ... read more
Wednesday, December 7, 2011
- Decision Resources to Release Bladder Cancer Drug Market Forecast Through 2020Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, will release a market forecast of the bladder cancer drug-treated population ... read more
Tuesday, December 6, 2011
- Despite a Near-Term Decline, the Drug Market for Addiction Disorders Will Increase from Just under $2 Billion in 2010 to More Than $2.4 Billion in 2020Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite a near-term decline in the overall size of the ... read more
Wednesday, November 30, 2011
- Therapies to Treat Chronic Back Pain and Arthritis Pain Will Continue to Be the Most Lucrative Segments of the Chronic Pain Drug Market Through 2020Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, together, therapies to treat chronic back pain and arthritis pain ... read moreBy 2015, the Brazilian Acute Coronary Syndrome Drug Market Will Nearly Double to $229 MillionDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in Brazil will ... read more